Healthcare Industry News: S.A.
News Release - October 22, 2012
Nuvo and Galderma Announce FDA Approval of Pliaglis(R)
MISSIS.A.GA, ON, Oct. 22, 2012 -- (Healthcare Sales & Marketing Network) - Nuvo ReS.A.ch Inc. (NRI.TO), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced that the U.S. Food and Drug Administration (FDA) haS.A.proved a supplemental New Drug Application (sNDA) for Pliaglis® (lidocaine/tetracaine) 7%/7% Cream. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.Pliaglis iS.A.topical local anesthetic cream that uses Nuvo's proprietary phase-changing technology to form a pliable peel on the skin when exposed to air. Pliaglis is indicated for use on intact skin in adults to provide local analgeS.A.for superficial aesthetic procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing and laser-assisted tattoo removal.
"We are very pleased that the sNDA for Pliaglis has been approved by the FDA," said Francois Fournier, President of U.S. and Canadian operations of Galderma Laboratories. "Pliaglis offerS.A.pre-treatment solution and contributes to improving the patient experience of an aesthetic treatment."
"This is yet another significant milestone for Nuvo this year," said Dr. Bradley Galer, President of Nuvo's Pain Group. "Pliaglis iS.A. important part of Nuvo's expanded topical pain product portfolio."
Important Safety Information
Indication: PLIAGLIS® Cream 7% / 7% is indicated for use on intact skin in adults to provide topical local analgeS.A.for superficial dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. Adverse Events: In clinical studies, the most common local reactions were erythema (47%), skin discoloration (16%), and edema (14%). These reactions were generally mild and transient, resolving spontaneously soon after treatment. The most common systemic adverse events were headache, vomiting, dizziness, and fever, all of which occurred with a frequency of <1%. Warnings/Precautions: Methemoglobinemia has been associated with use of local anesthetics such as tetracaine. PLIAGLIS® Cream should be used with caution in patients with sensitivity to any of its components, including para-aminobenzoic acid (PABA), and in patients with severe hepatic diS.A.e. PLIAGLIS® Cream is contraindicated in patients with a known history of sensitivity to lidocaine or tetracaine, or local anesthetics of the amide or ester type. When using PLIAGLIS® Cream in conjunction with other local anesthetic agents, the total dose of anesthetic should be calculated. Contact with the eyes should be avoided.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
About Nuvo ReS.A.ch Inc.
Nuvo ReS.A.ch iS.A.publicly traded, Canadian specialty pharmaceutical company, headquartered in MissiS.A.ga, Ontario. The Company is building a portfolio of products for the treatment of pain through internal reS.A.ch and development and by in-licensing and acquisition. The Company's product portfolio includes Pennsaid®, PliagliS.A.d Synera®. Pennsaid, a topical nonsteroidal anti-inflammatory drug (NSAID), is used to treat the signS.A.d symptoms of osteoarthritis of the knee(s). Pennsaid is sold in the United S.A.es by Mallinckrodt Inc., a Covidien company, in Canada by Paladin Labs Inc. and in several European countries. Pliaglis iS.A.topical local anesthetic cream which provides topical local analgeS.A.for superficial dermatological procedures. The Company has licensed worldwide marketing rights to Pliaglis to Galderma Pharma S.A., a global specialty pharmaceutical company specialized in dermatology. Synera iS.A.topical patch that combines lidocaine, tetracaine and heat, approved in the United S.A.es to provide local dermal analgeS.A.for superficial venouS.A.cesS.A.d superficial dermatological procedureS.A.d in Europe, for surface anaestheS.A.of normal intact skin. Nuvo currently markets Synera in the United S.A.eS.A.d its licensing partner, Eurocept International B.V., has initiated a pan-European launch of Synera (under the name Rapydan®) in several European countries. The Company iS.A.so developing the compound WF10, for the treatment of immune related diS.A.es. Further more information, please visit www.nuvoreS.A.ch.com.
About Galderma
Galderma iS.A.global pharmaceutical company founded in 1981 and exclusively focused on dermatology. The company has 31 wholly-owned affiliates with a worldwide network of distributorS.A.d 4,000 employees. Galderma's extensive product portfolio iS.A.ailable in 70 countrieS.A.d treatS.A.range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence. In 2011, Galderma acquired Q-Med, a Swedish medical device company specialized in aesthetics, strengthening Galderma's presence in the aesthetic and corrective market.
With approximately 19% of revenues invested each year to discover and develop new productS.A.d access innovative technologies, the company is one of the world's leading investors in dermatology R&D. Four S.A.e-of-the-art R&D centers, of which Sophia Antipolis in France is one of the largest dermatology sites in the world, and four manufacturing siteS.A.e dedicated to providing a wide range of innovative medical solutions which meet the highest S.A.dards of safety and efficacy. Strategic brands in the US include Epiduo®, Oracea®, Clobex®, Differin®, MetroGel®, Vectical® and Cetaphil®. For more information, please visit www.galdermausa.com.
Forward-Looking S.A.ements
This document contains forward-looking S.A.ements. Some forward-looking S.A.ements may be identified by words like "expects", "anticipates", "plans", "intends", "indicates" or similar expressions. These forward-looking S.A.ements, by their nature, neceS.A.ily involve riskS.A.d uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking S.A.ements. Nuvo considers the assumptions on which these forward-looking S.A.ementS.A.e based to be reasonable at the time they were prepared, but caution that these assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. FactorS.A.d risks, which could cause actual results to differ materially from current expectations, are discussed in the Company'S.A.nual Report, as well as in Nuvo'S.A.nual Information Form for the year ended December 31, 2011. Nuvo disclaimS.A.y intention or obligation to update or revise any forward-looking S.A.ements, whether aS.A.result of new information or future events, except as required by law. For additional information on riskS.A.d uncertainties relating to these forward looking S.A.ements, investors should consult the Company's ongoing quarterly filings, annual report and Annual Information Form and other filings found on SEDAR at www.sedar.com.
Source: Nuvo Research
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!